MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
GNE-495
CAS No. : 1449277-10-4
MCE 国际站:GNE-495
产品活性:GNE-495 是有效,选择性的 MAP4K4 抑制剂,IC50 值3.7 nM。
研究领域:MAPK/ERK Pathway
作用靶点:MAP4K
In Vitro: GNE-495 is a potent and selective MAP4K4 inhibitor with efficacy in retinal angiogenesis. GNE-495 shows the best balance of MAP4K4 inhibition, permeability, microsomal stability, and cellular potency.
In Vivo: GNE-495 is administered intraperitoneally to neonatal mouse pups at high doses: 25 and 50 mg/kg. GNE-495 shows good in vivo profile in all species tested, with low clearances, moderate terminal half-lives, and reasonable oral exposure levels (F=37-47%).
相关产品:Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | Anti-Cancer Compound Library | Oxygen Sensing Compound Library | Anti-Obesity Compound Library | Targeted Diversity Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Highly Selective Inhibitors Library | Serine/Threonine Kinase Inhibitor Library | Bioactive Compound Library Max | NCB-0846 | DMX-5804 | HPK1-IN-3 | PF-06260933 | NG25 | HPK1-IN-7 | GNE-1858 | KY-05009 | DS21150768 | MAP4K4-IN-3 | ZYF0033 | HPK1-IN-32 | GNE 220 hydrochloride | HPK1-IN-26 | SS47 TFA | TAK1/MAP4K2 inhibitor 1 | TL4-12 | HPK1-IN-4 | HPK1-IN-8 | DB1113 | HPK1-IN-34 | GNE-6893 | HPK1-IN-2 dihydrochloride | HPK1-IN-19 | FLT3/ITD-IN-4 | HMC-B17 | HPK1 antagonist-1
热门产品线:重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。